PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

Papatheodoridis, George; Dalekos, George; Sypsa, Vana; Yurdaydin, Cihan; Buti, Maria; Goulis, John; Luis Calleja, Jose; Chi, Heng; Manolakopoulos, Spilios; Mangia, Giampaolo; Gatselis, Nikolaos; Keskin, Onur; Savvidou, Savvoula; de la Revilla, Juan; Hansen, Bettina; Vlachogiannakos, Ioannis; Galanis, Kostantinos; İDİLMAN, RAMAZAN; Colombo, Massimo; Esteban, Rafael; Janssen, Harry; Lampertico, Pietro

doi:10.1016/j.jhep.2015.11.035

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Goulis J., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.64, sa.4, ss.800-806, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 64 Sayı: 4
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.jhep.2015.11.035
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.800-806
Anahtar Kelimeler: Hepatocellular carcinoma, Hepatitis B, Entecavir, Tenofovir, RECEIVING ENTECAVIR, CIRRHOSIS, SCORES, VALIDATION, LAMIVUDINE
Ankara Üniversitesi Adresli: Evet

Özet

Background & Aims: Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort study aimed to develop and validate an accurate HCC risk score in Caucasian CHB patients treated with the current oral antivirals, entecavir/tenofovir.